430 related articles for article (PubMed ID: 22520119)
1. Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam.
Shin S; Anh DD; Zaman K; Yunus M; Mai le TP; Thiem VD; Azim T; Victor JC; Dallas MJ; Steele AD; Neuzil KM; Ciarlet M
Vaccine; 2012 Apr; 30 Suppl 1():A106-13. PubMed ID: 22520119
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of the pentavalent rotavirus vaccine in African infants.
Armah GE; Breiman RF; Tapia MD; Dallas MJ; Neuzil KM; Binka FN; Sow SO; Ojwando J; Ciarlet M; Steele AD
Vaccine; 2012 Apr; 30 Suppl 1():A86-93. PubMed ID: 22520142
[TBL] [Abstract][Full Text] [Related]
3. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine.
Breiman RF; Zaman K; Armah G; Sow SO; Anh DD; Victor JC; Hille D; Ciarlet M; Neuzil KM
Vaccine; 2012 Apr; 30 Suppl 1():A24-9. PubMed ID: 22520132
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of the oral pentavalent rotavirus vaccine in Mali.
Sow SO; Tapia M; Haidara FC; Ciarlet M; Diallo F; Kodio M; Doumbia M; Dembélé RD; Traoré O; Onwuchekwa UU; Lewis KD; Victor JC; Steele AD; Neuzil KM; Kotloff KL; Levine MM
Vaccine; 2012 Apr; 30 Suppl 1():A71-8. PubMed ID: 22520140
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial.
Zaman K; Dang DA; Victor JC; Shin S; Yunus M; Dallas MJ; Podder G; Vu DT; Le TP; Luby SP; Le HT; Coia ML; Lewis K; Rivers SB; Sack DA; Schödel F; Steele AD; Neuzil KM; Ciarlet M
Lancet; 2010 Aug; 376(9741):615-23. PubMed ID: 20692031
[TBL] [Abstract][Full Text] [Related]
6. Methodology and lessons-learned from the efficacy clinical trial of the pentavalent rotavirus vaccine in Bangladesh.
Zaman K; Yunus M; El Arifeen S; Azim T; Faruque AS; Huq E; Hossain I; Luby SP; Victor JC; Dallas MJ; Lewis KD; Rivers SB; Steele AD; Neuzil KM; Ciarlet M; Sack DA
Vaccine; 2012 Apr; 30 Suppl 1():A94-100. PubMed ID: 22520143
[TBL] [Abstract][Full Text] [Related]
7. Malnutrition levels among vaccinated and unvaccinated children between 2 and 3 years of age following enrollment in a randomized clinical trial with the pentavalent rotavirus vaccine (PRV) in Bangladesh.
Feller AJ; Zaman K; Lewis KD; Hossain I; Yunus M; Sack DA
Vaccine; 2012 Apr; 30 Suppl 1():A101-5. PubMed ID: 22520118
[TBL] [Abstract][Full Text] [Related]
8. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa.
Tapia MD; Armah G; Breiman RF; Dallas MJ; Lewis KD; Sow SO; Rivers SB; Levine MM; Laserson KF; Feikin DR; Victor JC; Ciarlet M; Neuzil KM; Steele AD
Vaccine; 2012 Apr; 30 Suppl 1():A79-85. PubMed ID: 22520141
[TBL] [Abstract][Full Text] [Related]
9. A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children.
Dang DA; Nguyen VT; Vu DT; Nguyen TH; Nguyen DM; Yuhuan W; Baoming J; Nguyen DH; Le TL;
Vaccine; 2012 Apr; 30 Suppl 1():A114-21. PubMed ID: 22520120
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants.
Phua KB; Quak SH; Lee BW; Emmanuel SC; Goh P; Han HH; De Vos B; Bock HL
J Infect Dis; 2005 Sep; 192 Suppl 1():S6-S16. PubMed ID: 16088807
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of pentavalent rotavirus vaccine in Chinese infants.
Mo Z; Ma X; Luo P; Mo Y; Kaplan SS; Shou Q; Zheng M; Hille DA; Arnold BA; ; Liao X
Vaccine; 2019 Mar; 37(13):1836-1843. PubMed ID: 30808567
[TBL] [Abstract][Full Text] [Related]
12. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine.
Ciarlet M; Sani-Grosso R; Yuan G; Liu GF; Heaton PM; Gottesdiener KM; Arredondo JL; Schödel F
Pediatr Infect Dis J; 2008 Oct; 27(10):874-80. PubMed ID: 18756184
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix™) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007.
Anh DD; Carlos CC; Thiem DV; Hutagalung Y; Gatchalian S; Bock HL; Smolenov I; Suryakiran PV; Han HH
Vaccine; 2011 Mar; 29(11):2029-36. PubMed ID: 21256876
[TBL] [Abstract][Full Text] [Related]
14. Live attenuated tetravalent (G1-G4) bovine-human reassortant rotavirus vaccine (BRV-TV): Randomized, controlled phase III study in Indian infants.
Saluja T; Palkar S; Misra P; Gupta M; Venugopal P; Sood AK; Dhati RM; Shetty A; Dhaded SM; Agarkhedkar S; Choudhury A; Kumar R; Balasubramanian S; Babji S; Adhikary L; Dupuy M; Chadha SM; Desai F; Kukian D; Patnaik BN; Dhingra MS
Vaccine; 2017 Jun; 35(28):3575-3581. PubMed ID: 28536027
[TBL] [Abstract][Full Text] [Related]
15. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity.
Ciarlet M; He S; Lai S; Petrecz M; Yuan G; Liu GF; Mikviman E; Heaton PM; Panzer F; Rose T; Koller DY; Van Damme P; Schödel F
Pediatr Infect Dis J; 2009 Mar; 28(3):177-81. PubMed ID: 19209092
[TBL] [Abstract][Full Text] [Related]
16. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, including among HIV-infected and HIV-exposed infants.
Laserson KF; Nyakundi D; Feikin DR; Nyambane G; Cook E; Oyieko J; Ojwando J; Rivers SB; Ciarlet M; Neuzil KM; Breiman RF
Vaccine; 2012 Apr; 30 Suppl 1():A61-70. PubMed ID: 22520138
[TBL] [Abstract][Full Text] [Related]
17. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.
Vesikari T; Clark HF; Offit PA; Dallas MJ; DiStefano DJ; Goveia MG; Ward RL; Schödel F; Karvonen A; Drummond JE; DiNubile MJ; Heaton PM
Vaccine; 2006 May; 24(22):4821-9. PubMed ID: 16621194
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial.
Armah GE; Sow SO; Breiman RF; Dallas MJ; Tapia MD; Feikin DR; Binka FN; Steele AD; Laserson KF; Ansah NA; Levine MM; Lewis K; Coia ML; Attah-Poku M; Ojwando J; Rivers SB; Victor JC; Nyambane G; Hodgson A; Schödel F; Ciarlet M; Neuzil KM
Lancet; 2010 Aug; 376(9741):606-14. PubMed ID: 20692030
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya.
Feikin DR; Laserson KF; Ojwando J; Nyambane G; Ssempijja V; Audi A; Nyakundi D; Oyieko J; Dallas MJ; Ciarlet M; Neuzil KM; Breiman RF
Vaccine; 2012 Apr; 30 Suppl 1():A52-60. PubMed ID: 22520137
[TBL] [Abstract][Full Text] [Related]
20. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants.
Clark HF; Bernstein DI; Dennehy PH; Offit P; Pichichero M; Treanor J; Ward RL; Krah DL; Shaw A; Dallas MJ; Laura D; Eiden JJ; Ivanoff N; Kaplan KM; Heaton P
J Pediatr; 2004 Feb; 144(2):184-90. PubMed ID: 14760258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
